We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vir Biotechnology, Inc. (VIR) Moves 14.8% Higher: Will This Strength Last?
Read MoreHide Full Article
Vir Biotechnology, Inc. (VIR - Free Report) shares soared 14.8% in the last trading session to close at $25.91. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.9% loss over the past four weeks.
Shares surged as Vir Biotechnology will be included in the S&P SmallCap 600 effective prior to the opening of trading on Apr 4. The news encouraged investors as any fund buying that index will be buying the stock. This will result in investors’ gain.
This company is expected to post quarterly earnings of $3.55 per share in its upcoming report, which represents a year-over-year change of +368.9%. Revenues are expected to be $681.4 million, up 34314.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Vir Biotechnology, Inc., the consensus EPS estimate for the quarter has been revised 40.4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on VIR going forward to see if this recent jump can turn into more strength down the road.
Vir Biotechnology, Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Bicycle Therapeutics PLC Sponsored ADR (BCYC - Free Report) , closed the last trading session 3.4% lower at $42.54. Over the past month, BCYC has returned -6.9%.
Bicycle Therapeutics PLC Sponsored ADR's consensus EPS estimate for the upcoming report has changed -8.1% over the past month to -$0.70. Compared to the company's year-ago EPS, this represents a change of +4.1%. Bicycle Therapeutics PLC Sponsored ADR currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vir Biotechnology, Inc. (VIR) Moves 14.8% Higher: Will This Strength Last?
Vir Biotechnology, Inc. (VIR - Free Report) shares soared 14.8% in the last trading session to close at $25.91. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.9% loss over the past four weeks.
Shares surged as Vir Biotechnology will be included in the S&P SmallCap 600 effective prior to the opening of trading on Apr 4. The news encouraged investors as any fund buying that index will be buying the stock. This will result in investors’ gain.
This company is expected to post quarterly earnings of $3.55 per share in its upcoming report, which represents a year-over-year change of +368.9%. Revenues are expected to be $681.4 million, up 34314.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Vir Biotechnology, Inc., the consensus EPS estimate for the quarter has been revised 40.4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on VIR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Vir Biotechnology, Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Bicycle Therapeutics PLC Sponsored ADR (BCYC - Free Report) , closed the last trading session 3.4% lower at $42.54. Over the past month, BCYC has returned -6.9%.
Bicycle Therapeutics PLC Sponsored ADR's consensus EPS estimate for the upcoming report has changed -8.1% over the past month to -$0.70. Compared to the company's year-ago EPS, this represents a change of +4.1%. Bicycle Therapeutics PLC Sponsored ADR currently boasts a Zacks Rank of #3 (Hold).